Search clinical trials for: complete molecular response

Total 109757 results

Merck Sharp & Dohme LLC

Recruiting

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

Non Small Cell Lung Cancer

United States, Israel, Taiwan, Korea, Republic of, Switzerland, Hong Kong
Henan Cancer Hospital

Not yet recruiting

Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer

Breast Cancer | HER2-positive Breast Cancer

China
Erasmus Medical Center

Recruiting

Nivolumab Dose Optimization in Patients With a Complete, Partial or Stable Response (NIVOPTIMIZE)

Melanoma

Netherlands
Henan Cancer Hospital

Recruiting

Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC

Breast Cancer | HER2-positive Breast Cancer

China
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Early Stage Triple-Negative Breast Carcinoma

United States, Puerto Rico
Ruijin Hospital
The First Affiliated Hospital of Anhui Medical University; The First Affiliated... and other collaborators

Recruiting

Genotype-guided Treatment in Newly Diagnosed PTCL (THEORY)

Peripheral T Cell Lymphoma

China
AstraZeneca
SWOG Clinical Trials Partnerships; Daiichi Sankyo

Recruiting

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

Breast Cancer

United States, China, Denmark, United Kingdom, Korea, Republic of, Canada, Germany, Italy, Belgium, Spain, Japan, France, Taiwan, Greece, Brazil, Sweden, Puerto Rico
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation (JANUS)

Stage III Rectal Cancer AJCC v8 | Stage II Rectal Cancer AJCC v8 | Locally Advanced Rectal Carcinoma

United States, Puerto Rico
Guangdong Provincial People's Hospital

Recruiting

Patient-reported Outcomes in Preoperative Immunochemotherapy/Radiotherapy-treated Esophageal Cancer Patients (PICCRT)

Esophageal Squamous Cell Carcinoma | Immunotherapy | Patient-reported Outcomes

China
VA Office of Research and Development
VA Palo Alto Health Care System; VA Puget Sound Health Care System; Michael E... and other collaborators

Not yet recruiting

A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer

Esophageal Adenocarcinoma | Esophageal Squamous Cell Carcinoma | Gastroesophageal Junction Carcinoma

United States
Renmin Hospital of Wuhan University

Recruiting

Short-course Radiotherapy Combined With Neoadjuvant Chemotherapy and PD-1 Inhibitor in the Treatment of Locally Advanced Gastric Adenocarcinoma

Disorder in Complete Remission in Response to Treatment

China
Zhenzhen Liu

Recruiting

Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer

Breast Cancer | Triple Negative Breast Cancer | Camrelizumab

China
YULISU
Ono Pharmaceutical Co. Ltd

Recruiting

Neoadjuvant Nivolumab for Upper Tract Urothelial Carcinoma

Upper Urinary Tract Urothelial Carcinoma

Taiwan
Peking University First Hospital

Recruiting

Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therapy

Neoadjuvant Therapy | Cisplatin | Immunotherapy | HER2-negative Breast Cancer | Pathological Complete Response | Vinorelbine

China
Ottawa Hospital Research Institute
Ontario Institute for Cancer Research; Intensity Therapeutics, Inc.

Recruiting

INVINCIBLE TRIAL: Intratumoral INT230-6 in Breast Cancer

Breast Cancer

Canada
Zhejiang Cancer Hospital

Not yet recruiting

Neoadjuvant Short-course Radiotherapy Followed by the Combination of Immunotherapy and Chemotherapy in Locally Advanced Rectal Cancer

Locally Advanced Rectal Cancer

China
Ruijin Hospital
The First Affiliated Hospital of Anhui Medical University; The First Affiliated... and other collaborators

Recruiting

Pre-Operative Pembrolizumab + Chemoradiation in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma (PALACE-2)

Esophageal Squamous Cell Carcinoma

China
Lund University Hospital
Danish Breast Cancer Cooperative Group; Swedish Breast Cancer Group; Finnish... and other collaborators

Recruiting

NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC

Breast Cancer | Triple Negative Breast Neoplasms

Denmark, Sweden
David Garcia Cinca
Fundacion Clinic per a la Recerca Biomédica

Not yet recruiting

Omission of Surgery and Sentinel Lymph Node Dissection in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti- HER2-based Neoadjuvant Therapy (ELPIS Trial) (ELPIS)

Mammary Cancer

Spain
Dallas VA Medical Center

Recruiting

Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer

Gastroesophageal Junction Adenocarcinoma | Esophagus Adenocarcinoma | Esophagus Squamous Cell Carcinoma

United States
Jonsson Comprehensive Cancer Center
Tesaro, Inc.; Translational Research in Oncology-U.S

Recruiting

Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Advanced Malignant Solid Neoplasm | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Extensive Stage Lung Small Cell Carcinoma | Stage IIIC Lung Cancer AJCC v8

United States
Gustave Roussy, Cancer Campus, Grand Paris

Recruiting

Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2) (NIVO-ALCL)

Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma

France, Denmark, Netherlands
Hospital JP Garrahan
Hospital Pereyra Rosell, Montevideo, Uruguay

Recruiting

Pediatric Hodgkin Lymphoma Treatment Trial With Low Cumulative Doses of Chemotherapy Agents and Reduced Radiation. (LHGALOP2017)

Pediatric Hodgkin's Disease

Argentina
Peking University People's Hospital
Xijing Hospital; Beijing Friendship Hospital; Peking Union Medical College Hospital and other collaborators

Recruiting

Effect of Concurrent Capecitabine-based Long-term Radiotherapy Followed by XELOX Plus TME in Patients With High Risk Rectal Cancer: a Multi-centers, Randomized Controlled, Open-Label Trial (EXPLORE)

Rectal Cancer | Pathological Complete Response | Disease Free Survival

China
The First Hospital of Jilin University
First Affiliated Hospital Xi'an Jiaotong University; Qingdao University; First... and other collaborators

Recruiting

Sequential Neo-adjuvant Chemotherapy Followed by Capecitabine Vs. Conventional Adjuvant Chemotherapy in Breast Cancer (NACVCAC)

Breast Neoplasm Female

China
University of Maryland, Baltimore
Vanderbilt University

Recruiting

Dose Response of Epinephrine (Epineprhine)

Diabetes Complications

United States
Lund University
South Sweden Breast Cancer Group; Mrs. Berta Kamprad Foundation; U-CAN

Recruiting

Sweden Cancerome Analysis Network - Breast : Genomic Profiling of Breast Cancer (SCAN-B)

Breast Neoplasms

Sweden
American University of Beirut Medical Center

Recruiting

Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous Leukemia

Chronic Myelogenous Leukemia

Lebanon
QuantumLeap Healthcare Collaborative

Recruiting

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (I-SPY)

Breast Cancer | Breast Neoplasms | Breast Tumors | HER2-positive Breast Cancer | Angiosarcoma | Locally Advanced Breast Cancer | HER2-negative Breast Cancer | TNBC - Triple-Negative Breast Cancer | Hormone Receptor Positive Tumor | Hormone Receptor Negative Tumor | Early-stage Breast Cancer

United States
M.D. Anderson Cancer Center
Ariad Pharmaceuticals

Terminated

Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP)

Leukemia

United States
Roswell Park Cancer Institute

Active, not recruiting

Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

Hodgkin Lymphoma | Waldenstrom Macroglobulinemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Plasma Cell Myeloma | Myeloproliferative Neoplasm | Minimal Residual Disease | Graft Versus Host Disease | Severe Aplastic Anemia | Acute Myeloid Leukemia in Remission | Adult Acute Lymphoblastic Leukemia... and other conditions

United States
AstraZeneca
Merck Sharp & Dohme LLC; GOG Foundation; Myriad Genetic Laboratories, Inc.

Active, not recruiting

Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. (SOLO-1)

Advanced Ovarian Cancer | Newly Diagnosed | FIGO Stage III-IV | Partial Response | Complete Response | BRCA Mutation | First Line Platinum Chemotherapy

Korea, Republic of, France, Italy, United States, Israel, Canada, China, Brazil, United Kingdom, Poland, Australia, Japan, Netherlands, Russian Federation, Spain
M.D. Anderson Cancer Center

Active, not recruiting

Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive | B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Untreated Adult Acute Lymphoblastic Leukemia | Accelerated Phase Chronic Myelogenous Leukemia,... and other conditions

United States
University of Birmingham

Active, not recruiting

A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC) (ALL-RIC)

Acute Lymphoblastic Leukemia

United Kingdom
AstraZeneca

Active, not recruiting

Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy (L-MOCA)

Relapsed Ovarian Cancer | Following Complete or Partial Response to Platinum Based Chemotherapy | Platinum Sensitive

China, Malaysia
Organon and Co

Completed

A Study to Evaluate the Effects of Ezetimibe (MK-0653) on the Postprandial (Following a Meal) Lipoprotein Response in Participants With Primary Hypercholesterolemia (High Cholesterol) (MK-0653-072)(COMPLETED)

Hypercholesterolemia
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy

Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage IIB Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer... and other conditions

United States
AstraZeneca
Merck Sharp & Dohme LLC; European Network of Gynaecological Oncological Trial... and other collaborators

Active, not recruiting

Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

Relapsed Ovarian Cancer | Following Complete or Partial Response to Platinum Based Chemotherapy | Platinum Sensitive | BRCA Mutated

Korea, Republic of, France, China, Italy, United States, Israel, United Kingdom, Canada, Japan, Germany, Brazil, Netherlands, Belgium, Poland, Australia, Russian Federation, Spain
AbbVie

Active, not recruiting

Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma

Mantle Cell Lymphoma (MCL)

Japan
University Health Network, Toronto

Completed

Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC Trial) (ACDC-RP)

Prostate Cancer

Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy

Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast Cancer AJCC v8 | Prognostic Stage IIIC Breast Cancer AJCC v8 | Breast Inflammatory Carcinoma

United States
University of Washington
Oregon Health and Science University; National Institute of General Medical... and other collaborators

Terminated

Genetic and Dietary Predictors of Anti-platelet Response

Platelet Function

United States
Sun Yat-sen University

Active, not recruiting

TNT to Increase the Clinical Complete Response Rate for Distal LARC (TESS)

Chemoradiation | Rectal Cancer | Rectal Cancer Stage II | Rectal Cancer Stage III

China
Sun Yat-sen University
First Affiliated Hospital, Sun Yat-Sen University; Sun Yat-Sen Memorial Hospital...

Active, not recruiting

ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC

Breast Cancer | Neoadjuvant Chemotherapy

China
Satish R. Raj
National Center for Advancing Translational Sciences (NCATS)

Active, not recruiting

Treatment of Orthostatic Intolerance

Tachycardia | Chronic Orthostatic Intolerance

United States
ppharmaand GmbH
Bristol-Myers Squibb; Gynecologic Oncology Group; European Network of Gynaecological... and other collaborators

Active, not recruiting

A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA)

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal | Newly Diagnosed | FIGO Stage III-IV | Partial Response | Complete Response

United States, United Kingdom, Korea, Republic of, Russian Federation, Canada, Denmark, Taiwan, New Zealand, Ireland, Japan, Spain, Australia, Israel, Italy, Greece, Sweden, Czechia, Finland, Poland, Belgium, Germany, Romania, Singa... and more
Ospedale Policlinico San Martino
CRO "Centro Clinical Trials" IRCCS Ospedale Policlinico San Martino; Laboratory...

Withdrawn

Niraparib Maintenance Treatment in mCRC With a Partial o Complete Response After Oxaliplatin-based Induction Therapy (Bohème)

Metastatic Colorectal Cancer
Merck Sharp & Dohme LLC

Active, not recruiting

Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

Hepatocellular Carcinoma

United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, China, Denmark, France, Germany, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Malaysia, New Zealand, Norway, Poland, Russian Federation, Spai... and more
AbbVie

Completed

A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis (RA) Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs (SELECTSUNRISE)

Rheumatoid Arthritis

Japan
Cancer Trials Ireland

Terminated

CharactHer. ICORG 12-09, V3

HER2-positive Breast Cancer | TNM Stage II-IV Breast Cancer

Ireland, Italy

Search clinical trials for: complete molecular response

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ukraine

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations